Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A concise guide on Which Altcoins Are Good For Beginners, outlining practical picks and quick assessment tips so newcomers can invest with clarity.
19,874 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Blue Origin is pursuing a $130 billion private-market valuation, signaling a bold push by jeff bezos’s space company ...
Palantir faces a pivotal moment as 2025 results reinforce growth in AI-related revenue, yet lofty valuations keep inv...
A crypto-focused venture outfit scores a $1.2 billion fund rise, signaling a major shift toward AI and robotics along...
If you’re building a retirement roadmap, long-horizon stock bets can compound your wealth. Here are two healthcare-fo...
Iran headlines sparked a brief risk-off move, but crypto markets recovered quickly as talks progressed. Bitcoin and E...
President Trump issues an emergency payroll directive for TSA workers as the DHS shutdown drags on, hoping to relieve...
Micron stock retreats after a spring rally, renewing the debate over whether the memory chip maker has peaked. Analys...
Three dividend aristocrats have boosted payouts for a combined 187 years, delivering steady passive income for invest...
NVIDIA outperformed the wider semiconductor complex last week as AI demand strengthens its growth trajectory, leading...
Coinbase announced a 14% workforce cut to accelerate a lean, AI-native operating model amid ongoing crypto market vol...
Vertex’s $10 billion cash bid for Crinetics sparked a sharp rally, lifting the stock nearly to the offer price as tra...